In this context, we studied two CD19-targeting CAR-T-cell agents provided by Allogenica (France) against a human lymphoma model derived from the Raji cell line, to evaluate the chicken CAM assay as an alternative in vivo model for CAR-T-cell therapy testing. This evidence concerns the gene CD19 and lymphoma.